Metagone Biotech Australia

Metagone Biotech is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and metabolic diseases. The company's lead candidate, MG-S-2525, is a potent and selective small molecule inhibitor of the apical sodium-dependent bile acid transporter (ASBT) currently being evaluated in Phase 2 clinical trials for the treatment of primary biliary cholangitis (PBC). Metagone leverages its expertise in bile acid metabolism to address significant unmet medical needs in hepatology, including metabolic dysfunction-associated steatohepatitis (MASH). The company maintains operations in Taiwan and Australia to facilitate global clinical development and R&D tax efficiencies. Through its targeted approach, Metagone aims to provide next-generation treatments for patients with chronic cholestatic and metabolic liver conditions.